Pharmaxis Ltd (AU:SNT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Syntara Ltd has successfully raised A$15 million through a two-tranche placement, bolstering its cash reserves to approximately A$21.7 million. This capital will support various clinical trials and drug development initiatives, including those for myelofibrosis and Parkinson’s, as well as general operational expenses. The strong backing from institutional and high net worth investors reflects confidence in Syntara’s ongoing research and development programs.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.